OPTN Stock Overview
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
OptiNose, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.97 |
52 Week High | US$2.10 |
52 Week Low | US$0.85 |
Beta | -0.24 |
1 Month Change | -35.49% |
3 Month Change | -33.72% |
1 Year Change | -46.24% |
3 Year Change | -73.78% |
5 Year Change | -90.21% |
Change since IPO | -94.91% |
Recent News & Updates
Recent updates
There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump
Mar 01Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price
Dec 28OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%
May 23The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically
Mar 09OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M
Aug 11OptiNose: Potential Winner In Chronic Sinusitis Treatment
Jun 16OptiNose: Underappreciated Potential
Mar 10OptiNose: Undiscovered Gem
Aug 31OptiNose: Growing Sales Make The Current Market Cap Look Very Low
Jul 19OptiNose, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 09OptiNose EPS beats by $0.03, beats on revenue
May 05OptiNose's Business Is Thriving While OptiNose Trades At Lower Revenue Multiples Than Peers
Dec 01OptiNose EPS beats by $0.06, beats on revenue
Nov 05Shareholder Returns
OPTN | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -5.1% | 0.9% | 1.2% |
1Y | -46.2% | 13.9% | 24.7% |
Return vs Industry: OPTN underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: OPTN underperformed the US Market which returned 19.3% over the past year.
Price Volatility
OPTN volatility | |
---|---|
OPTN Average Weekly Movement | 11.1% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OPTN's share price has been volatile over the past 3 months.
Volatility Over Time: OPTN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 132 | Ramy Mahmoud | www.optinose.com |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
OptiNose, Inc. Fundamentals Summary
OPTN fundamental statistics | |
---|---|
Market cap | US$109.01m |
Earnings (TTM) | -US$35.48m |
Revenue (TTM) | US$70.99m |
1.5x
P/S Ratio-3.1x
P/E RatioIs OPTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OPTN income statement (TTM) | |
---|---|
Revenue | US$70.99m |
Cost of Revenue | US$8.63m |
Gross Profit | US$62.35m |
Other Expenses | US$97.84m |
Earnings | -US$35.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.31 |
Gross Margin | 87.84% |
Net Profit Margin | -49.99% |
Debt/Equity Ratio | -150.4% |
How did OPTN perform over the long term?
See historical performance and comparison